◼ Archived
Business
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
Novartis strikes a massive licensing agreement worth up to $7.8 billion with China-based biotech firm Abogen.
Novartis
30 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Novartis takes rights to Abogen’s mRNA T cell engager for $575M upfront
Novartis secures the rights to Abogen’s mRNA T cell engager in a massive $575 million upfront transaction.
◼ Archived
Business
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
Novartis has agreed to a massive new mRNA drug deal with Chinese startup Abogen worth up to $7.8 billion.
◼ Archived
Business
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Roche's experimental drug sefaxersen meets its primary endpoint in a late-stage study for the autoimmune disease IgAN.
◼ Archived
Business
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.
◼ Archived
Business
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
Telix's $2.35 billion merger with ITM signals a bold move into radiopharmaceuticals, drawing analyst optimism.
◼ Archived
Business
Novartis ends ALS program after phase 2 flop, adding to R&D woes
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novartis’ TREM2 drug fails Phase 2 ALS trial
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
A Promising Heart Drug Failed. What Went So Wrong?
The failure of heart drug trials from pharmaceutical giants Novartis and Novo Nordisk creates a significant setback for a promising field of medicine.
◼ Archived
Business
🔮 fades ✗
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
A major Novartis shareholder is demanding a board overhaul following a series of costly drug trial setbacks and strategic failures.
◼ Archived
Business
🔮 fades ✓
How Novartis' Double-Stacked Failures Shook Biotech
Novartis is facing significant scrutiny within the biotech sector following a series of dual failures that have impacted investor confidence.
◼ Archived
Business
🔮 fades ✗
Novartis Stock Tanks Following Third Major Pipeline Setback
Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.
◼ Archived
Business
🔮 fades ✓
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
◼ Archived
Business
🔮 fades ✗
Cholesterol drug setback casts doubt over multibillion-dollar race
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.
◼ Archived
Business
🔮 fades ✓
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
Novartis shares experienced their worst single-day drop in over two decades following the failure of a crucial phase 3 trial for an Avidity buyout drug.
◼ Archived
Business
🔮 fades ✗
Novartis’s Latest Trial Setback Sinks Stock
Novartis shares drop significantly following multiple trial setbacks and difficult dealmaking in the pharmaceutical sector.
◼ Archived
Business
🔮 fades ✗
Novartis cholesterol setback tests hopes for emerging heart disease drugs
Novartis shares decline after its cholesterol drug pelacarsen failed a critical late-stage cardiovascular trial, impacting expectations for heart disease treatments.
◼ Archived
Business
🔮 fades ✗
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
Novartis and Ionis face setbacks as a high-stakes Phase 3 trial for an Lp(a) cardiovascular drug fails to meet its primary goals.
◼ Archived
Business
🔮 fades ✓
Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Novartis inks $3.2B subcutaneous delivery deal with Alteogen
Novartis has entered a multi-billion dollar agreement to utilize Alteogen's subcutaneous drug delivery technology.
◼ Archived
Business
🔮 fades ✓
Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis shares climb following positive late-stage trial results for its experimental oral multiple sclerosis drug, Rhapsido.
◼ Archived
Business
🔮 fades ✗
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers Squibb halt autoimmune CAR-T trials following patient deaths, impacting the sector.
◼ Archived
Business
🔮 fades ✗
Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✓
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers Squibb halt multiple CAR-T clinical trials for autoimmune diseases following patient deaths and safety reviews.
◼ Archived
Health
🔮 fades ✗
Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
A close look at the new cholesterol guidelines, plus the role of diet
Updated 2026 cholesterol guidelines are prompting a renewed focus on statin safety data, dietary roles, and blood pressure management.
◼ Archived
Business
🔮 fades ✗
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA has issued a complete response letter rejecting ITM's radiopharmaceutical therapy ITM-11, a drug positioned to compete with Novartis treatments.
◼ Archived
Business
🔮 holds
Novartis to Buy Myricx Bio for Up to $1.5 Billion
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.